Clairvoyant Therapeutics
29.11.2023 22:46:30 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.
"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.
"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."
Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.
Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).
About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.
Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov
-30-
For more information:
Damian Kettlewell
damian@clairvoyantrx.com
SOURCE: Clairvoyant Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP Launches Unison Express to Fast-Track Supply Chain Planning from Ambition to Early Value27.5.2026 15:00:00 CEST | Press release
Ready-to-deploy solution delivers value quickly through proven industry best practices ANTWERPEN, BE / ACCESS Newswire / May 27, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, today announced the launch of Unison Express - an industry-specific, ready-to-deploy planning offering for mid-market companies looking to move beyond the tools and processes they have outgrown. Unison Express enables teams to realize value quickly while establishing a strong planning foundation that scales with their business over time. From spreadsheets to structured planning Organizations across industries face mounting pressure to modernize supply chain planning. Yet implementation projects can feel long, costly, and difficult to justify, especially when teams still rely on tools and processes they have outgrown, such as spreadsheets, legacy systems, and manual coordination. The result is higher operational risk and slower, less coordinated decision-making. Unison Express bridge
SINTEF Selects Power to Hydrogen to Produce Green Hydrogen for the PYROCO2 EU Green Deal Project in Norway27.5.2026 10:35:00 CEST | Press release
Power to Hydrogen's Second Commercial Project Extends Industrial-Scale AEM Electrolysis Into Chemicals Manufacturing COLUMBUS, OH / ACCESS Newswire / May 27, 2026 / Power to Hydrogen (P2H2), a developer of anion exchange membrane (AEM) electrolyzer systems, today announced a binding commercial order from SINTEF, one of Europe's largest research institutes, for a half-megawatt AEM electrolyzer system scheduled to be delivered in Q4 2026. The system will be deployed at SINTEF's facility in Tiller, Norway, where it will produce green hydrogen for a novel gas fermentation process that combines green hydrogen and captured carbon dioxide to produce zero-emission acetone, a platform chemical used across solvents, plastics, and industrial value chains. The order is Power to Hydrogen's second commercial project, following the company's landmark project at the Port of Antwerp-Bruges - set to be commissioned this summer - and marks an important expansion of AEM electrolysis into green chemicals a
Caldwell Strengthens Consumer and Private Equity Capabilities with Addition of Gabino Stuyck in Madrid27.5.2026 09:30:00 CEST | Press release
TORONTO, ON AND MADRID, ES / ACCESS Newswire / May 27, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Gabino Stuyck as a Partner in the firm's Consumer Practice. Based in Madrid, Stuyck's appointment expands Caldwell's presence in Europe and strengthens the firm's capabilities across consumer, private equity, technology, sports, and digital transformation leadership assignments globally. Caldwell welcomes Gabino Stuyck as a partner in the firm's Consumer Practice, strengthening the firm's global consumer and private equity capabilities. Based in Madrid, Stuyck advises private equity firms, portfolio companies, and global organizations on senior executive and board appointments across Europe, the Middle East, Latin America, and North America. With more than 17 years of executive search experience and more than 200 completed mandates worldwide, he is recognized for building high-impact leadership teams in investor-backed, high-growth
LinkShadow is Positioned in the Visionaries Quadrant in the 2026 Gartner(R) Magic Quadrant(TM) for Network Detection and Response (NDR)23.5.2026 17:00:00 CEST | Press release
Recognized for Vision. Driven by Innovation. Advancing AI-powered network detection and response through connected intelligence, contextual visibility, and modern cyber defense. ATHENS, GA / ACCESS Newswire / May 23, 2026 / LinkShadow has been positioned in the Visionaries Quadrant of the 2026 Gartner® Magic Quadrant™ for Network Detection and Response. We are recognized for our completeness of vision and ability to execute. We believe this recognition highlights a differentiated approach to NDR that is redefining how organizations detect and respond to modern network threats. As cyber threats grow more sophisticated and fast moving, security teams are challenged by fragmented visibility, overwhelming alert volumes, and limited context. LinkShadow addresses these challenges through a distinct strategy that combines AI driven analytics with deep contextual awareness and real time correlation across network activity. This enables organizations to move beyond isolated alerts and toward a
LiberNovo Summer Kickoff Across Europe: A Five-Day Flash and Two Show Floors22.5.2026 11:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / May 22, 2026 / LiberNovo's Summer Kickoff Flash opens Friday, May 22 across the EU (9:00 CEST) and UK (8:00 BST) and runs five days. LiberNovo Omni ships in a regional bundle with €651 off in the EU and £549.50 off in the UK. Verified students and educators can stack another 5% on top. What's in the Bundle EU: LiberNovo Omni paired with the StepSync footrest and a matching StepSync Mat. €1,066 flash, regular €1,717, or 38% off. UK: LiberNovo Omni paired with the StepSync footrest and an Eye Mask. £969.50 flash, regular £1,519, or 36% off. Designed Around Motion LiberNovo Omni adapts to the body in real time. Three features handle the work: Bionic FlexFit Backrest. Eight independent panels follow the spine through every shift in posture, instead of one rigid surface pushing back. Automatic armrests. They track with the chair's recline so you don't reset them between positions, and they slide back into the base when you scoot under the desk so they don't
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom